Ipsen casts doubt on Pfizer’s prostate plan
Mevrometostat is the only EZH2 inhibitor in phase 3 for prostate cancer.
Pfizer makes haste to go EZ
The company sticks with EZH2, despite others adding EZH1 inhibition.
Mevrometostat is the only EZH2 inhibitor in phase 3 for prostate cancer.
The company sticks with EZH2, despite others adding EZH1 inhibition.
